Inhibitor of osteoclastic bone resorption. Prevents osteoporosis and skeletal fractures, particularly in patients with multiple myeloma or prostate cancer. Also used to treat hypercalcemia. Inhibition of acid sphingomyelinase (aSMase) with an IC50 5µm.
Product Details
| Alternative Name: | 1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid, CGP 42446 |
| |
| Formula: | C5H10N2O7P2 . H2O |
| |
| MW: | 272.1 . 18.0 |
| |
| Source: | Synthetic. |
| |
| CAS: | 165800-06-6 |
| |
| MI: | 14: 10187 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in 0.1N NaOH. Sparingly soluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy: M.A. de Witte, et al.; Biol. Blood Marrow Transplant.
24, 1152 (2018),
Abstract;
Full Text
Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231: H. Bühler, et al.; In Vivo
30, 761 (2016),
Application(s): Cancer stem-like cells ,
Abstract;
A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma: R. N. Howie, et al.; PLoS One
10, e0132520 (2015),
Application(s): Injection via rat tail vein,
Abstract;
Full Text
Potent and Selective Inhibition of Acid Sphingomyelinase by Bisphosphonates.: AG. Roth, et al.; Angew. Chem. Int. Ed. Engl.
48, 7560 (2009),
Abstract;
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis: D.M. Black, et al.; New Engl. J. Med.
356, 1809 (2007),
Abstract;
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis: J.J. Body; Expert Opin. Pharmacother.
4, 567 (2003),
Abstract;
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma: F. Saad, et al.; J. Natl. Cancer Inst.
94, 1458 (2002),
Abstract;
Intravenous zoledronic acid in postmenopausal women with low bone mineral density: I.R. Reid, et al.; New Engl. J. Med.
346, 653 (2002),
Abstract;
An enzyme inhibition assay for the quantitative determination of the new bisphosphonate zoledronate in plasma: F. Risser, et al.; J. Pharm. Biomed. Anal.
15, 1877 (1997),
Abstract;
Clinical research update: zoledronate: J.J. Body; Cancer
80, 1699 (1997),
Abstract;
Full Text
Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound: J.R. Green, et al.; J. Bone Miner. Res.
9, 745 (1994),
Abstract;
